arrow
H

Hironori Tanaka

takarazuka city hospital
H指数:22
被引数:1,634

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

肝内肿瘤负荷对接受阿替利珠单抗联合贝伐珠单抗治疗的合并肝外转移的肝细胞癌患者预后的影响

2026-04-100
PRE
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan

肝病患者就业状况:一项在日本进行的国家问卷调查

2025-10-040
OAAI
Clinical Utility of a Prognostic Scoring System Based on LDH and CRP in HCC Patients Receiving Atezolizumab Plus Bevacizumab

基于LDH和CRP的预后评分系统在应用阿替利珠单抗联合贝伐珠单抗治疗的HCC患者中的临床应用价值

2025-09-190
PRE
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis

度鲁特玛联合特瑞普利单抗在合并门静脉血栓和高肿瘤负荷的肝细胞癌患者中的有效性与安全性:一项多中心回顾性分析

2025-09-060
PRE
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
2025-02-090
PRE
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

老年营养风险指数和新开发的评分系统可作为lenvatinib治疗不可切除的肝细胞癌患者的预后预测

2025-01-021
OAAI
Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease
2024-05-012
PRE
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents

开发直接抗病毒药物后,日本丙型肝炎病毒引起的肝细胞癌患者临床结局的变化

2024-04-112
PRE
Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study
2024-02-290
PRE
Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study

代谢功能障碍相关脂肪肝与胆结石发生的关系: 一项纵向研究

2024-01-112
PRE